The chart uses daily closes adjusted by the available provider. There may be delays, gaps or differences versus the official source.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Compares H1 2025 with H2 2025, summing every instrument of the company each fund holds. A fund switching instrument within the same company doesn't show up here as an entry or exit — for that instrument-by-instrument detail, see the Instruments section.
New positions: 5Exits: 1Increasing exposure: 4Reducing exposure: 0
+ MI CARTERA RV USA ADVISED BY, FI
Enters the position at 1.43% weight.
+ MULTIADVISOR GESTION, FI
Enters the position at 1.09% weight.
+ GESTION BOUTIQUE VI, FI
Enters the position at 3.14% weight.
+ CAIXABANK MULTISALUD, FI
Enters the position at 1.35% weight.
+ SMART GESTION FLEXIBLE, FI
Enters the position at 0.91% weight.
− DUNAS SELECCIÓN USA ESG CUBIERTO FI
Leaves the position; it weighed 0.24%.
Objective ratios
FCF yield
5.9%
Net debt / EBITDA
1.80x
P/E
—
52-week range
42.52 – 68.64 USD
Data as-is, not an interpretation: it does not say whether the price is cheap or expensive, and it is not a buy or sell recommendation.
Updated 2026-09-06. Source: Yahoo Finance.
Disclaimer
This is not financial advice. Weights come from the periodic reports each manager files with the CNMV and lag the real close of the period. Price, description and ratios, when available, come from Yahoo Finance and may not exactly match this ISIN if the company has multiple share classes.